Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Obtains CE Mark for Ion Torrent Genexus Dx Integrated Sequencer

NEW YORK – Thermo Fisher Scientific said on Tuesday that it received CE-IVD marking for the Ion Torrent Genexus Dx Integrated Sequencer this month and is making the platform commercially available for diagnostic testing and clinical research.

"With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital — including regional and community hospitals — can bring [next-generation sequencing] in house, giving clinicians access to timely, comprehensive genomic profiling results," said Garret Hampton, president of clinical NGS and oncology at Thermo Fisher, in a statement.

The company said it is also developing a sample-to-report diagnostic workflow and a portfolio of clinically validated assays for the Genexus, including comprehensive genomic profiling and hemato-oncology assays.

Thermo Fisher has been offering the research-use-only version of the Ion Torrent Genexus since its launch in late 2019.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.